Open an account

Celldex Therapeutics

CLDX · NASDAQ

$30.29+$0.62 (+2.09%)TodayMarket closed ·
Prev close $29.67

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 198 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Employees
198
Headquarters
Hampton, New Jersey
Listed
May 15, 1986
Sector
Health Care
Industry
Biotechnology
Website
celldex.com

CLDX key statistics

Market cap
2.38B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.38M
Volume
1.10M
Open price
$29.99
High today
$30.82
Low today
$29.61
52 Week high
$45.14
52 Week low
$22.10

Celldex Therapeutics (CLDX) at a glance

Celldex Therapeutics (CLDX) last traded at $30.29, with a market cap of 2.38B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $29.61 and $30.82. The current price is 2.3% above the day's low and 1.7% below its high.

Volume so far is 1.10M shares, below the average of 2.38M shares a day.

Over the past year Celldex Therapeutics has ranged from $22.10 to $45.14, and now sits 36% of the way up that range.

Celldex Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.94 per share against an estimate of -$1.08.

The average analyst price target is $64.33, 112.4% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 12 analyst ratings say Buy
  • Buy91.7%
  • Hold8.3%
  • Sell0.0%
Price target · 16 analystsAvg $64.33
Low
$28.28
Now
$30.29
High
$105.00

CLDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 6.8% on average.

  1. Q3 FY24: reported -$0.64 per share against an estimate of -$0.686
  2. Q4 FY24: reported -$0.71 per share against an estimate of -$0.749
  3. Q1 FY25: reported -$0.81 per share against an estimate of -$0.7701
  4. Q2 FY25: reported -$0.85 per share against an estimate of -$0.8729
  5. Q3 FY25: reported -$1.01 per share against an estimate of -$0.9187
  6. Q4 FY25: reported -$1.22 per share against an estimate of -$1.03
  7. Q1 FY26: reported -$1.18 per share against an estimate of -$1.16
  8. Q2 FY26: reported -$0.94 per share against an estimate of -$1.08

CLDX news

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

  • Avi Kapoor

    Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results

  • Vandana Singh

    Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

  • Press releaseGlobe Newswire

    Celldex Reports Second Quarter Financial Results and Provides Corporate Update

  • Vandana Singh

    Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Celldex Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.